Adrenergic hypersensitivity after beta-blocker withdrawal in hypertrophic cardiomyopathy.
Withdrawal of beta-blocker therapy has been associated with the development of adrenergic hypersensitivity and adverse clinical effects in patients with coronary artery disease and hypertension. The aim of this study was to establish the occurrence and clinical significance of adrenergic hypersensitivity after abrupt withdrawal of long-term beta blockade in hypertrophic cardiomyopathy. Beta-adrenergic sensitivity was measured using the isoprenaline chronotropic dose25. Symptom assessment chronotropic dose25 calculation, bicycle exercise, echocardiography and Holter monitoring were performed while the patient received beta-blocker therapy and repeated on days 2, 4, 6, 8 (acute withdrawal period) and on day 21 after abrupt withdrawal. The study was terminated after 7 patients had been studied because all patients experienced a marked deterioration in symptoms and several clinical events had occurred. The chronotropic dose25 (mean +/- standard deviation) demonstrated beta 1-adrenergic hypersensitivity with a minimal value of 1.6 +/- 0.8 micrograms during the acute withdrawal period compared with 3.8 +/- 1.7 micrograms on day 21 (p = 0.003). Heart rates during rest and exercise showed an overshoot increase during the acute withdrawal period. The maximal 24-hour ventricular ectopic count was higher during the acute withdrawal period than during day 21 (p = 0.04). Of 3 patients with inducible outflow tract gradients, 2 developed resting gradients greater than 30 mm Hg during the acute withdrawal period. There was an increase in peak late filling velocity of mitral inflow after beta-blocker withdrawal. In conclusion, transient beta-adrenergic hypersensitivity occurs after beta-blocker withdrawal in hypertrophic cardiomyopathy and is associated with significant physiologic changes and adverse clinical consequences.
Gilligan
D M
DM
Clinical Cardiology (Department of Medicine), Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.
Chan
W L
WL
Stewart
R
R
Oakley
C M
CM
D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000139:chemically induced; D001262:Atenolol / Q000009:adverse effects*; D002312:Cardiomyopathy, Hypertrophic / Q000150:complications / Q000188:drug therapy*; D003327:Coronary Disease / Q000139:chemically induced; D004342:Drug Hypersensitivity / Q000209:etiology*; D004452:Echocardiography; D015150:Echocardiography, Doppler; D015716:Electrocardiography, Ambulatory; D005080:Exercise Test; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007545:Isoproterenol / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011433:Propranolol / Q000009:adverse effects*; D013375:Substance Withdrawal Syndrome
D001262:Atenolol; D011433:Propranolol; D007545:Isoproterenol